Montelukast Pensa (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Pensa, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for maintenance therapy of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in appropriate patients.

GNH USA supplies Montelukast Pensa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction. - Asthma: provides maintenance therapy that reduces the frequency and severity of asthma attacks. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergies. - Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity, improving exercise tolerance.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Dizziness: brief episodes. - Fatigue: mild tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: depression, mood changes, or suicidal thoughts. - Hepatic enzyme elevation: potential liver function abnormalities. - Eosinophilic granulomatosis with polyangiitis: rare vasculitic syndrome. - Stevens‑Johnson syndrome: severe skin reaction. - Severe bronchospasm: paradoxical worsening of breathing.

When prescribing Montelukast, clinicians should consider several safety aspects. - Pregnancy: safety not established; use only if potential benefit outweighs risk. - Breastfeeding: assess risk versus benefit; limited data available. - Liver impairment: use with caution and monitor hepatic function. - Concomitant enzyme inducers (e.g., phenobarbital, rifampin): may reduce drug exposure. - Neuropsychiatric monitoring: observe for mood changes or suicidal ideation. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital: induces metabolism, lowering Montelukast levels. - Rifampin: strong enzyme inducer that reduces therapeutic exposure. - Ketoconazole: may increase Montelukast concentrations, raising risk of side effects.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR; monitor coagulation parameters. - Beta‑agonists: additive bronchodilatory effect; watch for excessive stimulation. - Theophylline: may increase plasma concentrations; consider dose adjustment.